VLDLR Antibody

PACO20857



Size:	Protein Background:
50ul	Anti-apoptotic protein which acts by inhibiting the activities of CASP3, CASP7 and
Reactivity:	CASP9. Can inhibit the autocleavage of pro-CASP9 and cleavage of pro-CASP3 by CASP9. Capable of inhibiting CASP9 autoproteolysis at 'Asp-315' and decreasing the
Human, Mouse, Rat	rate of auto proteolysis at 'Asp-330'. Acts as a mediator of neuronal survival in pathological conditions. Prevents motor-neuron apoptosis induced by a variety of
Source:	signals. Possible role in the prevention of spinal muscular atrophy that seems to be
Rabbit	caused by inappropriate persistence of motor-neuron apoptosis: mutated or deleted forms of NAIP have been found in individuals with severe spinal muscular atrophy. Acts
lsotype:	as a sensor component of the NLRC4 inflammasome that specifically recognizes and binds needle protein CprI from pathogenic bacteria C. violaceum. Association of
lgG	pathogenic bacteria proteins drives in turn drive assembly and activation of the NLRC4
Applications:	inflammasome, promoting caspase-1 activation, cytokine production and macrophage pyroptosis.
ELISA, IHC	Gene ID:
Recommended dilutions:	VLDLR
ELISA:1:2000-1:10000, IHC:1:30-1:150	Uniprot
	P98155
	Synonyms:
	very low density lipoprotein receptor
	Immunogen:
	Synthetic peptide of human VLDLR.
	Storage:

-20° C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol





The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using PACO20857(VLDLR Antibody) at dilution 1/40, on the right is treated with synthetic peptide. (Original magnification: x—200).

The image on the left is immunohistochemistry of paraffin-embedded Human liver cancer tissue using PACO20857(VLDLR Antibody) at dilution 1/40, on the right is treated with synthetic peptide. (Original magnification: x—200).